Zealand Pharma A/S
ZLDPF
$62.50
-$0.79-1.25%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -61.42% | -98.49% | 223.87% | 11.89% | -2.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.42% | -98.49% | 223.87% | 11.89% | -2.51% |
| Cost of Revenue | -96.57% | -229.39% | 280.13% | -- | -- |
| Gross Profit | -25.38% | -96.17% | 55.90% | -22.20% | -51.86% |
| SG&A Expenses | 139.28% | 90.45% | 44.01% | 61.77% | 20.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5,922.08% | 308.43% | -- | -- | -- |
| Total Operating Expenses | 50.96% | 42.67% | 44.84% | 50.19% | 2.84% |
| Operating Income | -61.73% | -878.64% | -35.31% | -53.28% | -3.38% |
| Income Before Tax | -8.80% | -470.99% | 9.55% | -19.00% | 15.89% |
| Income Tax Expenses | 0.36% | -5.36% | 16.05% | 19.17% | 58.56% |
| Earnings from Continuing Operations | -8.82% | -462.53% | 9.51% | -19.33% | 15.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.82% | -462.53% | 9.51% | -19.33% | 21.51% |
| EBIT | -61.73% | -878.64% | -35.31% | -53.28% | -3.38% |
| EBITDA | -61.74% | -799.94% | -41.11% | -246.31% | 0.66% |
| EPS Basic | 10.19% | -399.46% | 16.15% | 0.30% | 32.01% |
| Normalized Basic EPS | 4.42% | -435.63% | -49.71% | -116.71% | 35.51% |
| EPS Diluted | 10.19% | -409.30% | 16.15% | 0.30% | 32.01% |
| Normalized Diluted EPS | 4.42% | -446.35% | -49.71% | -116.71% | 35.51% |
| Average Basic Shares Outstanding | 21.18% | 21.03% | 7.91% | 19.67% | 26.35% |
| Average Diluted Shares Outstanding | 21.18% | 17.22% | 7.91% | 19.67% | 26.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
